ArticleBreast (Edinburgh, Scotland)2026

Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.

Junji Tsurutani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.